2018-04-27 11:46
The subsidiary Biovica Inc is a sales company based in Delaware. The purpose of the US subsidiary is to establish DiviTum on the US market. DiviTum measures cell proliferation rate and the objective is to provide information regarding treatment efficacy...
2018-04-24 10:08
In accordance with the above guidelines, the Nomination Committee for the 2018 Annual General Meeting will consist of the following persons: The members of the Nomination Committee together represent approximately 33 percent of the shares and 47 percent...
2018-04-17 08:30
The study, presented at the ongoing AACR congress in Chicago, concluded that using DiviTum to measure cell proliferation in blood samples could potentially be used to assess cell cycle modulation by Ibrance®. “We are pleased that DiviTum is...
2018-03-28 08:00
The study, consisting of 31 patients with metastatic breast cancer, was performed at the Prato Hospital, Italy. The results are published in the scientific journal Oncotarget and demonstrates that DiviTum can evaluate efficacy of standard hormonal therapy...
2018-03-20 08:00
The value of the order is approximately 100 000 USD. "New and more effective cancer treatment are important in order to improve patient outcome. At the same time, it’s expensive to develop new cancer drugs. With DiviTum, we aim to provide value...
2018-02-22 11:53
100 women with metastasized breast cancer will be included in the study, with the objective to find markers to identify early development of resistance of today's standard treatment in combination with Ibrance®. By early identification of women...
2017-12-05 08:30
Adam has experience in production management and process development. He has worked, among other things, to develop and implement new production methods in ISO13485-certified medical technology companies. Adams previous professional experiences include...
2017-11-23 08:00
Led by Dr Cynthia Ma, the study investigated 50 women with breast cancer treated with standard endocrine therapy in combination with Ibrance® prior to surgery. DiviTum® was used to measure cell proliferation rate in blood samples collected before...
2017-11-21 08:00
The proof of concept study, including 404 patients, provides evidence for using DiviTum as a dynamic biomarker before and during therapy to give important answers regarding prognosis and how effective therapy is. Biovica’s assay was prognostic for...
2017-11-14 08:00
With imaging methods used for evaluating the effect of treatment, it takes about three months to evaluate whether the given therapy is effective or not. The new study demonstrates that DiviTum® accurately can predict outcome (progression free- and...
>4,500
Numbers of patients in studies
28
Publications
22
Pharma Projects